Back to Search Start Over

Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature.

Authors :
Hye Won Lee
Moon Jae Chung
Huapyong Kang
Heun Choi
Youn Jeong Choi
Kyung Joo Lee
Seung Woo Lee
Seung Hyuk Han
Jin Seok Kim
Si Young Song
Source :
Gut & Liver; Jan2014, Vol. 8 Issue 1, p109-112, 4p, 2 Diagrams, 1 Chart
Publication Year :
2014

Abstract

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
19762283
Volume :
8
Issue :
1
Database :
Complementary Index
Journal :
Gut & Liver
Publication Type :
Academic Journal
Accession number :
93875233
Full Text :
https://doi.org/10.5009/gnl.2014.8.1.109